Unveiling Expert Insights on the PSE Test
with Dr. Pohlman and Dr. Heaton

Category: PSE

Read Time: 2 Minutes

Last updated: 08 February 2024

In our latest blog post, we are delighted to share an exclusive episode of The Prostate Health Podcast featuring our distinguished Laboratory Medical Director, Dr. Robert Heaton. The episode features a conversation with the highly regarded Dr. Garrett Pohlman, a board-certified Urologist. Dr. Pohlman leads a prominent private Urology group in the Midwest and has already treated over 4,000 men with various prostate conditions.

During this episode, Dr. Pohlman and Dr. Heaton discuss the transformative benefits of the innovative EpiSwitch® Prostate Screening Test (PSE), a blood test developed and validated by Oxford BioDynamics and launched in September 2023. This test, now a cornerstone of our commitment to advancing personalized healthcare, demonstrates an exceptional 94% accuracy.

The PSE test demonstrates an exceptional 94% accuracy.

The PSE test empowers urologists and patients alike, providing valuable insights into predicting prostate cancer presence through a simple blood test, saving valuable time in getting the proper care. The test's superior performance can reduce the number of men referred for an unnecessary biopsy and treatment.

Prostate cancer is the second most commonly occurring cancer and the second leading cause of cancer deaths, affecting 1 in 8 men.

Dr. Heaton, an esteemed board-certified pathologist, addresses the challenges associated with prostate cancer detection and emphasizes the crucial role of early screening. Prostate cancer is the second most commonly occurring cancer and the second leading cause of cancer deaths, affecting 1 in 8 men. The conversation explores the limitations of traditional tests like the prostate-specific antigen (PSA) test. PSA levels can be high or rising for many reasons other than prostate cancer. In fact, 3 in 4 men with a high PSA are found not to have prostate cancer upon biopsy. In contrast, other patients with normal PSA levels can still have prostate cancer.

In fact, 3 in 4 men with a high PSA are found not to have prostate cancer upon biopsy.

Delving into the prevalence of prostate cancer and early detection strategies, Dr. Heaton shares insights into the optimal timing for prostate cancer screening and underscores the pivotal role the EpiSwitch® PSE test plays in determining the presence or absence of prostate cancer.

As part of our ongoing mission to educate the public on the critical aspects of prostate health, this episode is a testament to our dedication. It concludes with practical information on accessing the EpiSwitch PSE test, emphasizing its recent availability in the US and UK.

Curious to learn more about PSE and the significance of accurate prostate cancer testing? Explore our previous post, "Time to rethink prostate cancer testing: A Q&A with OBD's CSO, Alexandre Akoulitchev, PhD, FRSM" or visit 94percent.com.

Stay In the Loop

Subscribe to receive our latest blog posts
Topics from groundbreaking discoveries to cutting-edge advancements and industry trends.

SHARE THIS POST

Learn more about EpiSwitch® Prostate Screening Test (PSE)
The 94% accurate prostate cancer blood test

Detect prostate cancer risk from blood with 94% accuracy. An effective screening test that identifies an individual’s current risk of prostate cancer from blood. PSE is administered alongside or following a standard PSA test to significantly boost screening performance and reduce the number of men referred for unnecessary biopsies and treatments.

This powerful test is valuable for identifying individuals requiring biopsy and those suitable for active surveillance without further testing.

Learn About PSE
Immune checkpoint inhibitor antibody bound to white blood cell receptor to block inactivation by tumor cells